

Supporting Information

Rec. Nat. Prod. 20:3 (2026):e25123763

An experimental and *in silico* study on the antifungal activity of guaianolides isolated from *Centaurea polypodiifolia* Boiss. against resistant *Candida* strains

Selin Tufan¹, Faika Başoğlu^{2,3}, Abdulilah Ece⁴, Dilek Şatana⁵,
Mahmut Miski¹ and Nur Tan^{1,*}

¹Department of Pharmacognosy, Faculty of Pharmacy, İstanbul University, İstanbul, Fatih 34116, Türkiye

²Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Near East University, Lefkoşa, Turkish Republic of Northern Cyprus

³DESAM Institute, Near East University, Lefkoşa, Turkish Republic of Northern Cyprus

⁴Department of Medical Biochemistry, Faculty of Medicine, Biruni University, İstanbul, Küçükçekmece 34295, Türkiye

⁵Department of Medical Microbiology, Faculty of Medicine, İstanbul University, İstanbul, Çapa 34093, Türkiye

*Corresponding author: E-Mail: nurtan@istanbul.edu.tr; Phone: 90 212-4400000-13400 Fax: 90 212-4400252

Table of Contents	Page
Figure S1: Isolation schema of DCM-M Extract	5
Figure S2: 1 (Cynaropicrin) 1D- ¹ H Proton NMR Spectrum	7
Figure S3: 1 (Cynaropicrin) stacked ¹ H NMR Spectra of different fractions	8
Table S1: 2 (Cynarinin A) HMBC, COSY, NOESY correlations (in CDCl ₃)	10
Figure S4: 2 (Cynarinin A) 1D- ¹ H Proton NMR Stacked Spectra in Different Solvents	11
Figure S5: 2 (Cynarinin A) ¹³ C (APT) 1D- NMR Stacked Spectra	12
Figure S6: 2 (Cynarinin A) COSY 2D-NMR Spectrum	13
Figure S7: 2 (Cynarinin A) HSQC 2D-NMR Spectrum	14
Figure S8: 2 (Cynarinin A) HMBC 2D-NMR Spectrum	15
Figure S9: 2 (Cynarinin A) NOESY 2D-NMR Spectrum	16

Figure S10: NOESY Correlations of 2 (Cynarinin A) (according to NOESY 2D-NMR spectrum in CDCl ₃)	17
Table S2: 2 (Cynarinin A) NOESY correlation (in CDCl ₃ :CD ₃ OD (95:5))	18
Figure S11: 2 (Cynarinin A) NOESY 2D-NMR Spectrum	19
Figure S12: NOESY Correlations of 2 (Cynarinin A) (according to NOESY 2D-NMR spectrum in CDCl ₃ :MeOD (95:5, v/v))	20
Figure S13: 3 novel compound, SciFinder® report	22
Table S3: 3 (Nourolide) HMBC, COSY, NOESY correlations (in CDCl ₃ :CD ₃ OD (95:5))	23
Figure S14: 3 (Nourolide) 1D- ¹ H Proton NMR Spectrum	24
Figure S15: 2 (Cynarinin A) and 3 (Nourolide 5) 1D- ¹ H Proton NMR Stacked Spectra	25
Figure S16: 3 (Nourolide) ¹³ C (APT) 1D-NMR Spectrum	26
Figure S17: 3 (Nourolide) COSY 2D-NMR Spectrum	27
Figure S18: 3 (Nourolide) HSQC 2D-NMR Spectrum	28
Figure S19: 3 (Nourolide) HMBC 2D-NMR Spectrum	29
Figure S20: 3 (Nourolide) NOESY 2D-NMR Spectrum	30
Figure S21: NOESY Correlations of 3 (Nourolide) (according to NOESY 2D-NMR spectrum in CDCl ₃ :MeOD (95:5, v/v))	31
Table S4: 3 (Nourolide) HMBC, COSY, NOESY correlations (in CD ₃ OD)	32
Figure S22: 3 (Nourolide) 1D- ¹ H Proton NMR Spectrum	33
Figure S23: 3 (Nourolide) ¹³ C (APT) 1D-NMR Spectrum	34
Figure S24: 3 (Nourolide) COSY 2D-NMR Spectrum	35
Figure S25: 3 (Nourolide) HSQC 2D-NMR Spectrum	36
Figure S26: 3 (Nourolide) HMBC 2D-NMR Spectrum	37
Figure S27: 3 (Nourolide) NOESY 2D-NMR Spectrum	38
Figure S28: NOESY Correlations of 3 (Nourolide) (according to NOESY 2D-NMR spectrum in MeOD)	39
Figure S29: MS (-) Spectrum of 3 (Nourolide)	40
Figure S30: UV Absorbance Spectrum of 3 (Nourolide)	41
Figure S31: Polarimeter measurement at 19.8 °C (0.5 mg/ml concentration)	41
Figure S32: IR Spectrum of 3 (Nourolide)	42

Table S5: 4 (Aguerin B) HMBC, COSY, NOESY correlations	44
Figure S33: 4 (Aguerin B) 1D- ¹ H Proton NMR Spectrum	45
Figure S34: 4 (Aguerin B) ¹³ C (APT) 1D-NMR Spectrum	46
Figure S35: 4 (Aguerin B) COSY 2D-NMR Spectrum	47
Figure S36: 4 (Aguerin B) HSQC 2D-NMR Spectrum	48
Figure S37: 4 (Aguerin B) HMBC 2D-NMR Spectrum	49
Figure S38: 4 (Aguerin B) NOESY 2D-NMR Spectrum	50
Table S6: 5 (Grosheimin) HMBC, COSY, NOESY correlations	52
Figure S39: 5 (Grosheimin) 1D- ¹ H Proton NMR Spectrum	53
Figure S40: 5 (Grosheimin) ¹³ C (APT) 1D-NMR Spectrum	54
Figure S41: 5 (Grosheimin) COSY 2D-NMR Spectrum	55
Figure S42: 5 (Grosheimin) HSQC 2D-NMR Spectrum	56
Figure S43: 5 (Grosheimin) HMBC 2D-NMR Spectrum	57
Figure S44: 5 (Grosheimin) NOESY 2D-NMR Spectrum	58
Table S7: 6 (Dehydrocynaropicrin) HMBC, COSY, NOESY correlations	60
Figure S45: 6 (Dehydrocynaropicrin) 1D- ¹ H Proton NMR Spectrum	61
Figure S46: 6 (Dehydrocynaropicrin) ¹³ C (APT) 1D-NMR Spectrum	62
Figure S47: 6 (Dehydrocynaropicrin) COSY 2D-NMR Spectrum	63
Figure S48: 6 (Dehydrocynaropicrin) HSQC 2D-NMR Spectrum	64
Figure 49: 6 (Dehydrocynaropicrin) HMBC 2D-NMR Spectrum	65
Figure S50: 6 (Dehydrocynaropicrin) NOESY 2D-NMR Spectrum	66
Table S8: 1A HMBC, COSY, NOESY correlations	68
Figure S51: 1A 1D- ¹ H Proton NMR Spectrum	69
Figure S52: 1A ¹³ C (APT) 1D-NMR Spectrum	70
Figure S53: 1A HSQC 2D-NMR Spectrum	71
Figure S54: 1A COSY 2D-NMR Spectrum	72
Figure S55: 1A HMBC 2D-NMR Spectrum	73
Figure S56: 1A NOESY 2D-NMR Spectrum	74
Table S9: 1B HMBC and COSY correlations	76

Figure S57: 1B 1D- ^1H Proton NMR Spectrum	77
Figure S58: 1B ^{13}C (APT) 1D-NMR Spectrum	78
Figure S59: 1B COSY 2D-NMR Spectrum	79
Figure S60: 1B HSQC 2D-NMR Spectrum	80
Figure S61: 1B HMBC 2D-NMR Spectrum	81





Figure S1: Isolation schema of DCM-M Extract

1. 1 (Cynaropicrin)



¹H NMR (500 MHz, CDCl₃); δ 6.34 (q, J = 0.9 Hz, 1H, 4'a), 6.23 (d, J = 3.4 Hz, 1H, 13a), 5.96 (q, J = 1.3 Hz, 1H, 4'b), 5.62 (d, J = 3.1 Hz, 1H, 13b), 5.50 (t, J = 1.9 Hz, 1H, 15a), 5.37 (t, J = 1.8 Hz, 1H, 15b), 5.15 (m, 2H, 8, 14a), 4.95 (d, J = 1.6 Hz, 1H, 14b), 4.57 (t, J = 7.5 Hz, 1H, 3), 4.39 (d, J = 4.6 Hz, 2H, 3'), 4.26 (dd, J = 10.6, 9.0 Hz, 1H, 6), 3.20 (tt, J = 9.4, 3.3 Hz, 1H, 7), 2.99 (dt, J = 10.8, 8.0 Hz, 1H, 1), 2.86 (ddt, J = 10.5, 8.8, 1.7 Hz, 1H, 5), 2.71 (dd, J = 14.6, 5.1 Hz, 1H, 9a), 2.40 (dd, J = 14.6, 3.8 Hz, 1H, 9b), 2.25 (m, 1H, 2a), 1.74 (ddd, J = 13.3, 11.0, 7.5 Hz, 1H, 2b).




Figure S2: 1 (Cynaropicrin) 1D-¹H Proton NMR Spectrum





Figure S3: 1 (Cynaropicrin) stacked ^1H NMR Spectra of different fractions

2. 2 (Cynarinin A)



^1H NMR (500 MHz, CDCl_3); δ 5.08 (s, 1H, 14b), 4.81 (m, 1H, 14a), 4.61 (d, J = 11.5 Hz, 1H, 13a), 4.40 (dd, J = 11.5, 1.7 Hz, 1H, 13b), 4.08 (dd, J = 10.1, 8.4 Hz, 1H, 6), 3.91 (td, J = 10.3, 5.5 Hz, 1H, 8), 3.13 (td, J = 8.1, 4.2 Hz, 1H, 1), 2.88 (dd, J = 12.3, 5.5 Hz, 1H, 9 β), 2.73 (t, J = 10.4 Hz, 1H, 7), 2.57 (m, 1H, 2 α), 2.49 (m, 1H, 2 β), 2.32 (m, 4H, 4, 5), 2.24 (dd, J = 12.3, 10.1 Hz, 1H, 9 α).

^1H NMR (500 MHz, CDCl_3 + CD_3OD (95:5)); δ 5.02 (s, 1H, 14a), 4.74 (s, 1H, 14b), 4.57 (d, J = 11.1 Hz, 1H, 13a), 4.32 (dd, J = 11.2, 2.0 Hz, 1H, 13b), 4.02 (dd, J = 10.1, 8.5 Hz, 1H, 6), 3.80 (td, J = 10.3, 5.6 Hz, 1H, 8), 3.10 (td, J = 8.2, 4.0 Hz, 1H, 1), 2.81 (dd, J = 12.4, 5.6 Hz, 1H, 9 β), 2.64 (t, J = 10.4 Hz, 1H, 7), 2.49 (m, 2H, 2), 2.27 (tt, J = 7.7, 3.6 Hz, 4H, 4, 5), 2.17 (dd, J = 12.3, 10.0 Hz, 1H, 9 α).

^{13}C NMR (126 MHz, CDCl_3); δ 218.05 (3), 174.87, 173.22 (12), 143.30 (10), 130.21, 129.82, 115.52 (14), 81.37 (6), 76.51 (11), 70.44 (8), 64.25 (13), 56.04, 51.46 (5), 48.37 (9), 47.40 (4), 43.39 (2), 39.78 (1), 34.17, 32.07, 24.88, 22.84, 14.73 (15).

^{13}C NMR (126 MHz, CDCl_3 + CD_3OD (95:5)); δ 218.95 (3), 173.12 (12), 143.76 (10), 114.91 (14), 81.70 (6), 76.28 (11), 69.92 (8), 64.39 (13), 55.90 (7), 51.44 (5), 48.34 (9), 47.38 (4), 43.38 (2), 39.67 (1), 14.61 (15).

Table S1: 2 (Cynarinin A) HMBC, COSY, NOESY correlations (*in CDCl₃*)

No	HMBC	COSY	NOESY
1	-	H5(2.32), H2 β (2.49), H2 α (2.57), H14a(4.81)	H5(2.32), H2 α (2.57)
2 α	C3(218.0), C5(51.5), C1(39.8), C10(143.3)	H1(3.13)	H1(3.13)
2 β	-	H1(3.13)	-
3	H2 α (2.57), H15(1.25)	-	-
4	C5(51.5)	H6(4.08), H15(1.25)	-
5	C4(47.4)	H1(3.13), H6(4.08)	H1(3.13), H15(1.25)
6	C4(47.4)	H4(2.32), H5(2.32), H7(2.73)	H8(3.91)
7	C5(51.5), C6(81.4), C8(70.4), C11(76.5), C13b(64.2)	H6(4.08), H8(3.91)	-
8	-	H7(2.73), H9 β (2.88), H9 α (2.24)	H6(4.08), H9 β (2.88), H13b(4.40), H13a(4.61)
9 α	C8(70.4), C14b(115.5)	H8(3.91), H9 β (2.88), H14b(5.08)	-
9 β	C1(39.8), C7(56.0), C8(70.4), C10(143.3), C14b(115.5)	H8(3.91), H9 α (2.24), H14b(5.08)	H8(3.91), H14b(5.08)
10	H2 α (2.57), H9 β (2.88)	-	-
11	H7(2.73), H13b(4.40)	-	-
12	H13b(4.40), H13a(4.61)	-	-
13a	C12(173.2)	-	H8(3.91)
13b	C12(173.2), C11(76.5)	-	H8(3.91)
14a	C1(39.8), C9 β (48.4)	H1(3.13)	-
14b	C1(39.8), C9 β (48.4)	H9 β (2.88), H9 α (2.24)	H9 β (2.88)
15	C3(218.0)	H4(2.32)	H5(2.32)




Figure S4: 2 (Cynarinin A) 1D-¹H Proton NMR Stacked Spectra in Different Solvents




Figure S5: 2 (Cynarinin A) ¹³C (APT) 1D- NMR Stacked Spectra




Figure S6: 2 (Cynarinin A) COSY 2D-NMR Spectrum







Figure S9: 2 (Cynarinin A) NOESY 2D-NMR Spectrum



Cynarinin A

According to NOESY 2D NMR Spectrum in CDCl₃
Energy = 350.2 kJ/mol



iSpartan (Version 1.4.10)
Wavefunction, Inc.

Figure S10: NOESY Correlations of 2 (Cynarinin A) (according to NOESY 2D-NMR spectrum in CDCl₃)

Table S2: 2 (Cynarinin A) NOESY correlation (*in CDCl₃:CD₃OD (95:5)*)

No	NOESY
1	H7(2.64)
2	H14b(4.74)
4	H6(4.02)
5	H7(2.64)
6	H4(2.27), H8(3.80), H13a(4.57)
7	H5(2.27), H1(3.10)
8	H6(4.02), H8(3.80), H13b(4.32), H13a(4.57)
13a	H6(4.02), H8(3.80)
13b	H8(3.80)
14b	H2(2.49)





Figure S12: NOESY Correlations of 2 (Cynarinin A) (according to NOESY 2D-NMR spectrum in CDCl₃:MeOD (95:5, v/v))

3. 3 (Nourolide)



¹H NMR (500 MHz, CD₃OD_SPE); δ 5.06 (s, 1H, 14a), 4.75 (s, 1H, 14b), 4.20 (m, 1H, 6), 4.17 (m, 1H, 8), 4.13 (m, 1H, 13b), 3.76 (d, *J* = 10.4 Hz, 1H, 13a), 3.21 (td, *J* = 8.8, 3.4 Hz, 1H, 1), 2.84 (dd, *J* = 12.4, 5.7 Hz, 1H, 9α), 2.61 (m, 1H, 7), 2.58 (m, 1H, 2α, 7), 2.45 (ddd, *J* = 19.0, 4.0, 1.2 Hz, 1H, 2β), 2.30 (m, 2H, 4, 5), 2.23 (ddd, *J* = 12.4, 9.8, 1.0 Hz, 1H, 9β), 1.20 (m, 3H, 15).

¹H NMR (500 MHz, CDCl₃ + CD₃OD (95:5)); δ 5.04 (s, 1H, 14'), 4.73 (d, *J* = 2.7 Hz, 1H, 14''), 4.03 (m, 2H, 6, 8), 3.83 (m, 2H, 13', 13''), 3.10 (td, *J* = 8.4, 4.3 Hz, 1H, 1), 2.83 (dd, *J* = 12.5, 5.5 Hz, 1H, 9α), 2.63 (t, *J* = 10.3 Hz, 1H, 7), 2.50 (m, 2H, 2', 2''), 2.26 (m, 3H, 4, 5), 2.19 (dd, *J* = 12.5, 10.1 Hz, 1H, 9β), 1.19 (d, *J* = 6.7 Hz, 3H, 15).

¹³C NMR (126 MHz, CD₃OD_SPE); δ 180.19 (12), 146.25 (10), 114.44 (14), 83.38, 79.60 (11), 70.79, 64.64 (13), 57.14 (7), 52.89 (5), 48.44 (4), 44.23 (2), 40.88 (1), 14.88 (15).

¹³C NMR (126 MHz, CDCl₃ + CD₃OD (95:5)); δ 177.26 (12), 143.93 (10), 114.93 (14), 81.97, 78.44 (11), 70.28, 62.71, 56.14, 51.57 (4), 47.66 (9), 47.34 (5), 43.54, 39.63, 14.48 (15).

CAS SciFinder

Enter a query...

Edit

Return to Home

Substances search for drawn structure

All Substances Reactions References Suppliers Patent Markush

View Related Results

Filter Results

Structure Match

As Drawn (0)

Substructure (0)

Similarity (45K)

Behavior

Filter by Exclude

5 New results

Similarity

Filtering: Similarity: 3 Selected X Number of Components: 1 X Clear All Filters

240 Results

Sort: Relevance View: Partial

1 95

849146-43-6

Absolute stereochemistry shown, Rotation (+)

$C_{15}H_{20}O_6$
(3*R*,3*aR*,4*S*,6*aR*,9*S*,9*aR*,9*bR*)-Octahydro-3,4-dihydroxy-3-(hydroxymethyl)-9-methyl-6-...

9 0 0

2 95

2143109-73-1

$C_{15}H_{20}O_6$
Octahydro-3,4-dihydroxy-3-(hydroxymethyl)-9-methyl-6-methyleneazuleno[4,5-*b*]fura...

1 0 0

3 94

83551-03-5

$C_{15}H_{20}O_5$
Octahydro-3-hydroxy-3-(hydroxymethyl)-9-methyl-6-methyleneazuleno[4,5-*b*]furan-2-...

14 0 5

Figure S13: 3 novel compound, SciFinder® report

Table S3: 3 (Nourolide) HMBC, COSY, NOESY correlations (*in CDCl₃:CD₃OD (95:5)*)

No	δ_{H}	δ_{C}	HMBC	COSY	NOESY
1	3.10 (td, $J=8.4,4.3$ Hz, 1H)	39.4	-	2.26(4), 2.26(5), 2.50(2b), 2.50(2a)	2.26(5), 2.63(7)
2a	2.50 (m, 1H)	43.4	51.6(4), 143.9(10),219.8(3)	3.10(1)	-
2b			51.6(4), 143.9(10),219.8(3)	3.10(1)	-
3	-	219.8	1.19(15),2.50(2b), 2.50(2a)	-	-
4	2.26 (m, 1H)	51.6	-	1.19(15),3.10(1), 4.04(6)	4.04(6)
5	2.26 (m, 1H)	47.3	-	1.19(15),3.10(1), 4.04(6)	1.19(15),3.10(1)
6	4.03 (m, 1H)	81.8	70.2(8)	2.26(4), 2.26(5), 2.63(7)	2.26(4)
7	2.63 (t, $J=10.3$ Hz, 1H)	56.0	47.7(9 β), 62.6(13b),70.2(8)	4.02(8),4.04(6)	3.10(1)
8	4.03 (m, 1H)	70.2	-	2.63(7), 2.83(9 α)	2.19(9beta)
9 α	2.83 (dd, 12.5,5.5 Hz, 1H)	47.7	39.4(1), 56.0(7), 70.2(8), 114.9(14b), 143.9(10)	2.19(9 β),4.02(8)	5.04(14a)
9 β	2.19 (dd, 12.5,10.1 Hz, 1H)	47.7	39.4(1), 70.2(8), 114.9(14b)	2.83(9 α)	4.02(8)
10	-	143.9	2.50(2b), 2.50(2a), 2.83(9 α), 4.73(14b), 5.04(14a)	-	-
11	-	78.4	3.83(13b), 3.83(13a)	-	-
12	-	177.3	3.83(13b), 3.83(13a)	-	-
13a	3.83 (m, 1H)	62.6	56.0(7), 78.4(11), 177.3(12)	-	-
13b			56.0(7), 78.4(11), 177.3(12)	-	-
14a	5.04 (s, 1H)	114.9	39.4(1), 47.7(9 β), 70.2(8), 143.9(10)	-	-
14b	4.73 (d, $J=2.7$ Hz, 1H)		39.4(1),47.3(5), 47.7(9 β), 70.2(8), 143.9(10)	-	2.83(9alpha)
15	1.19 (d, $J=6.7$ Hz, 3H)	14.5	81.8(6),219.8(3)	2.26(4), 2.26(5)	2.65 (5)




Figure S14: 3 (Nourolide) 1D-¹H Proton NMR Spectrum




Figure S15: 2 (Cynarinin A) and 3 (Nourolide 5) 1D-¹H Proton NMR Stacked Spectra




Figure S16: 3 (Nourolide) ¹³C (APT) 1D-NMR Spectrum




Figure S18: 3 (Nourolide) HSQC 2D-NMR Spectrum

© 2026 ACG Publications. All rights reserved.




Figure S19: 3 (Nourolide) HMBC 2D-NMR Spectrum









Figure S20: 3 (Nourolide) NOESY 2D-NMR Spectrum



Nourolide

According to NOESY 2D NMR Spectrum in MeOD:CDCl₃ (95:5, v/v)
Energy = 353.1 kJ/mol



iSpartan (Version 1.4.10)
Wavefunction, Inc.

Figure S21: NOESY Correlations of 3 (Nourolide) (according to NOESY 2D-NMR spectrum in CDCl₃:MeOD (95:5, v/v))

Table S4: 3 (Nourolide) HMBC, COSY, NOESY correlations (*in CD₃OD*)

No	HMBC	COSY	NOESY
1	-	H4(2.30), H5(2.30), H2β(2.45), H14b(4.75)	H5(2.30)
2α	C6(83.2)	-	-
2β	C10(146.2)	H1(3.21)	H14b(4.75)
4	-	H1(3.21), H6(4.19), H15(1.20)	-
5	-	H1(3.21), H6(4.19), H15(1.20)	H1(3.21), H15(1.20)
6	C4(48.4), C8(70.6)	H4(2.30), H5(2.30), H7(2.61), H8(4.17)	-
7	C6(83.2), C8(70.6), C11(79.6)	H6(4.19), H8(4.17)	-
8	-	H6(4.19), H7(2.61), H9β(2.23), H9α(2.84)	H9β(2.23)
9α	C1(40.9), C7(57.1), C8(70.6), C10(146.2), C11(79.6), C14b(114.4)	H8(4.17), H9β(2.23), H14a(5.06)	H14a(5.06)
9β	C1(40.9), C8(70.6), C10(146.2), C14b(114.4)	H8(4.17), H9α(2.84), H14a(5.06)	H1(3.21), H8(4.17)
10	H2β(2.45), H9β(2.23), H9α(2.84), H14b(4.75), H14a(5.06)	-	-
11	H7(2.61), H9α(2.84), H13b(4.13), H13a(3.76)	-	-
12	H13b(4.13), H13a(3.76)	-	-
13a	C7(57.1), C12(180.2), C11(79.6)	-	-
13b	C7(57.1), C12(180.2), C11(79.6)	-	-
14a	C1(40.9), C8(70.6), C9β(49.2), C10(146.2)	H9β(2.23), H9α(2.84)	H9α(2.84), H14b(4.75)
14b	C1(40.9), C8(70.6), C9β(49.2), C10(146.2)	H1(3.21)	H2β(2.45), H14a(5.06)
15	C4(48.4), C5(52.9), C6(83.2)	H4(2.30), H5(2.30)	H5(2.30)




Figure S22: 3 (Nourolide) 1D- ^1H Proton NMR Spectrum





Figure S23: 3 (Nourolide) ^{13}C (APT) 1D-NMR Spectrum











Figure S27: 3 (Nourolide) NOESY 2D-NMR Spectrum



Nourolide

According to NOESY 2D NMR Spectrum in MeOD
Energy = 353.1 kJ/mol



iSpartan (Version 1.4.10)
Wavefunction, Inc.

Figure S28: NOESY Correlations of 3 (Nourolide) (according to NOESY 2D-NMR spectrum in MeOD)

C:\Users\User\...RT-CP-13B-2.raw Injection 1 FTMS - p ESI F...0000-1500.0000] MS - spectrum 0.09




Figure S29: MS (-) Spectrum of 3 (Nourolide)




Figure S30: UV Absorbance Spectrum of 3 (Nourolide)





Figure S31: Polarimeter measurement at 19.8 °C (0.5 mg/ml concentration)



C:\Users\donanim\Desktop\bzk_2024\CP-13B.0


CP-13B

Instrument type and / or accessory

27.08.2024

Figure S32: IR Spectrum of 3 (Nourolide)

4. 4 (Aguerin B)



¹H NMR (500 MHz, CDCl₃); δ 6.21 (1H, d, J = 3.4 Hz, 3'b, 13b), 6.18 (1H, s, 3'b), 5.67 (1H, m, 3'a), 5.61 (1H, d, J = 3.1 Hz, 13a), 5.50 (1H, t, J = 1.9 Hz, 15b), 5.36 (1H, t, J = 1.8 Hz, 15a), 5.14 (1H, d, J = 1.6 Hz, 14a), 5.09 (1H, ddd, J = 9.5, 5.1, 3.9 Hz, H-8), 4.94 (1H, d, J = 1.6 Hz, 14b), 4.56 (1H, td, J = 7.1, 2.0 Hz, H-3), 4.24 (1H, dd, J = 10.6, 9.0 Hz, H-6), 3.19 (1H, tt, J = 9.3, 3.3 Hz, H-7), 2.98 (1H, dt, J = 10.8, 8.0 Hz, H-1), 2.86 (1H, m, H-5), 2.70 (1H, dd, J = 14.5, 5.2 Hz, 9β), 2.38 (1H, dd, J = 14.5, 3.9 Hz, 9α), 2.23 (1H, dt, J = 13.2, 7.4 Hz, 2β), 1.99 (3H, s, 4'), 1.73 (1H, ddd, J = 13.2, 11.0, 7.6 Hz, 2α)

¹³C NMR (126 MHz, CDCl₃); δ 169.28 (12), 166.50 (1'), 152.44 (4), 141.96 (10), 137.54 (11), 136.13 (2'), 126.72 (3'), 122.75, 118.21, 113.62 (15), 78.71 (6), 74.23 (8), 73.92 (3), 51.46 (5), 47.82 (7), 45.43 (1), 39.24 (2), 37.28 (9), 18.39 (4').

Table S5: 4 (Aguerin B) HMBC, COSY, NOESY correlations

No	HMBC	COSY	NOESY
1	51.5(5), 78.7(6), 118.2(14b), 142.0(10)	1.73(2 α), 2.23(2 β)	1.73(2 α), 2.86(5), 4.56(3)
2 α	45.4(1), 51.5(5), 73.9(3), 142.0(10)	2.23(2 β), 2.98(1), 4.56(3)	2.23(2 β), 2.98(1), 4.56(3)
2 β	51.5(5), 152.4(4)	1.73(2 α), 2.98(1), 4.56(3)	1.73(2 α)
3	113.6(15b), 152.4(4)	1.73(2 α), 2.23(2 β)	1.73(2 α), 2.98(1)
4	2.23(2 β), 2.86(5), 4.56(3), 5.36(15a), 5.49(15b)	-	-
5	39.2(2 β), 45.4(1), 78.7(6), 113.6(15b), 152.4(4)	4.24(6)	2.98(1), 3.19(7), 5.49(15b)
6	-	2.86(5), 3.19(7)	2.70(9 β), 5.09(8)
7	51.5(5), 74.2(8), 78.7(6), 137.5(11)	4.24(6), 5.09(8), 5.61(13a), 6.21(13b)	2.86(5), 5.61(13a)
8	-	2.38(9 α), 2.70(9 β), 3.19(7)	4.24(6)
9 α	118.2(14b), 142.0(10)	5.09(8)	2.70(9 β)
9 β	45.4(1), 118.2(14b), 142.0(10)	5.09(8)	2.38(9 α), 4.24(6)
10	1.73(2 α), 2.38(9 α), 2.70(9 β), 2.98(1), 5.14(14a)	-	-
11	3.19(7)	-	-
12	5.61(13a), 6.21(13b)	-	-
13a	47.8(7), 169.3(12)	3.19(7)	3.19(7), 6.18(3'b), 6.21(13b)
13b	47.8(7), 169.3(12)	3.19(7)	5.61(13a)
14a	37.3(9 β), 45.4(1), 142.0(10)	-	-
14b	37.3(9 β), 45.4(1)	-	-
15a	51.5(5), 73.9(3), 152.4(4)	-	-
15b	51.5(5), 73.9(3), 152.4(4)	-	2.86(5)
1'	1.99(4'), 5.67(3'a), 6.18(3'b)	-	-
2'	1.99(4'), 6.18(3'b)	-	-
3'a	18.4(4'), 166.5(1')	1.99(4')	1.99(4')
3'b	18.4(4'), 136.1(2'), 166.5(1')	1.99(4')	5.61(13a)
4'	126.7(3'b), 136.1(2'), 166.5(1')	5.67(3'a), 6.18(3'b)	5.67(3'a)




Figure S33: 4 (Aguerin B) 1D-¹H Proton NMR Spectrum




Figure S34: 4 (Aguerin B) ¹³C (APT) 1D-NMR Spectrum




Figure S35: 4 (Aguerin B) COSY 2D-NMR Spectrum





Figure S36: 4 (Aguerin B) HSQC 2D-NMR Spectrum

5. 5 (Grosheimin)



¹H NMR (500 MHz, CDCl₃); δ 6.36 (d, *J* = 3.3 Hz, 1H, 13b), 6.31 (d, *J* = 2.9 Hz, 1H, 13a), 5.08 (s, 1H, 14b), 4.83 (s, 1H, 14a), 3.98 (t, *J* = 9.1 Hz, 1H, 6), 3.90 (tt, *J* = 9.5, 5.5 Hz, 1H, 8), 3.17 (td, *J* = 8.1, 4.4 Hz, 1H, 1), 3.07 (tt, *J* = 9.2, 3.2 Hz, 1H, 7), 2.85 (dd, *J* = 12.9, 5.8 Hz, 1H, 9β), 2.55 (dd, *J* = 19.3, 8.6 Hz, 1H, 2α), 2.48 (dd, *J* = 19.4, 4.4 Hz, 1H, 2β), 2.39 – 2.24 (m, 3H, 4, 5, 9α), 2.03 (d, *J* = 5.5 Hz, 1H), 1.26 (d, *J* = 6.8 Hz, 3H, 15).

¹³C NMR (126 MHz, CDCl₃); δ 219.00 (3), 169.93 (12), 143.31 (10), 136.58 (11), 125.83 (13), 115.85 (14), 82.34 (6), 77.41, 77.16, 76.91, 73.34 (8), 51.34, 49.40 (7), 48.03 (9), 47.12 (5), 43.32 (2), 40.35 (1), 15.08 (15).

Table S6: 5 (Grosheimin) HMBC, COSY, NOESY correlations

No	HMBC	COSY	NOESY
1	51.2(4), 115.8(14b), 143.3(10),219.0(3)	2.30(4), 2.30(5), 2.31(9 α), 2.53(2 α), 4.83(14a)	2.30(5), 4.83(14a)
2 α	40.3(1), 51.2(4), 143.3(10),219.0(3)	3.17(1)	-
2 β	51.2(4)	-	4.83(14a)
3	1.26(15), 2.53(2 α),3.17(1)	-	-
4	15.1(15),40.3(1), 82.3(6)	1.26(15),3.17(1), 3.96(6)	-
5	15.1(15), 40.3(1),51.2(4), 73.3(8), 82.3(6), 115.8(14b)	1.26(15),3.17(1), 3.96(6)	1.26(15),3.17(1)
6	47.1(5), 73.3(8)	2.30(4), 2.30(5), 3.07(7)	3.90(8)
7	-	3.90(8),3.96(6), 6.31(13a), 6.36(13b)	2.31(9 α), 6.31(13a)
8	-	2.31(9 α), 2.85(9 β),3.07(7)	2.85(9 β),3.96(6)
9 α	40.3(1), 73.3(8), 82.3(6), 115.8(14b)	2.85(9 β),3.17(1), 3.90(8), 5.08(14b)	3.07(7)
9 β	40.3(1), 49.4(7), 73.3(8), 115.8(14b), 143.3(10)	2.31(9 α),3.90(8)	3.90(8), 5.08(14b)
10	2.53(2 α), 2.85(9 β),3.17(1), 4.83(14a), 5.08(14b)	-	-
12	6.31(13a),6.36(13b)	-	-
13a	49.4(7), 169.9(12)	3.07(7)	3.07(7)
13b	49.4(7), 169.9(12)	3.07(7)	-
14a	40.3(1), 48.0(9 β), 143.3(10)	3.17(1)	2.48(2 β),3.17(1), 5.08(14b)
14b	40.3(1), 48.0(9 β), 143.3(10)	2.31(9 α)	2.85(9 β), 4.83(14a)
15	47.1(5), 51.2(4),219.0(3)	2.30(4), 2.30(5)	2.30(5)




Figure S39: 5 (Grosheimin) 1D-¹H Proton NMR Spectrum




Figure S40: 5 (Grosheimin) ¹³C (APT) 1D-NMR Spectrum




Figure S41: 5 (Grosheimin) COSY 2D-NMR Spectrum

© 2026 ACG Publications. All rights reserved.




Figure S42: 5 (Grosheimin) HSQC 2D-NMR Spectrum




Figure S43: 5 (Grosheimin) HMBC 2D-NMR Spectrum





Figure S44: 5 (Grosheimin) NOESY 2D-NMR Spectrum

6. 6 (Dehydrocynaropicrin)



¹H NMR (500 MHz, CDCl₃); δ 6.35 (m, 1H, 3'b), 6.33 (d, J = 3.3 Hz, 1H, 13a), 6.30 (d, J = 2.4 Hz, 1H, 15b), 6.00 (q, J = 1.3 Hz, 1H, 3'a), 5.90 (dd, J = 2.4, 0.8 Hz, 1H, 15a), 5.86 – 5.77 (m, 1H, 13b), 5.13 (ddd, J = 10.3, 5.2, 2.3 Hz, 1H, 8), 5.09 (d, J = 4.2 Hz, 1H, 14a), 4.90 (s, 1H, 14b), 4.40 (s, 3H, 4'), 4.20 – 4.05 (m, 1H, 6), 3.43 (ddt, J = 12.2, 8.9, 3.1 Hz, 1H, 7), 3.33 – 3.25 (m, 1H, 5), 3.22 (td, J = 8.2, 5.1 Hz, 1H, 1), 2.92 (dd, J = 13.5, 5.8 Hz, 1H, 9 β), 2.68 – 2.58 (m, 1H, 2 α), 2.57 – 2.49 (m, 1H, 2 β), 2.33 (dt, J = 13.4, 6.6 Hz, 1H, 9 α).

¹³C NMR (126 MHz, CDCl₃); δ 143.66 (4), 141.49 (10), 139.27 (2'), 127.00 (3'), 125.05 (13), 123.72 (15), 118.06 (14), 79.87 (6), 74.54 (8), 62.49 (4'), 49.14 (5), 46.78 (7), 43.49 (2), 41.79 (9), 40.60 (1).

Table S7: 6 (Dehydrocynaropicrin) HMBC, COSY, NOESY correlations

No	HMBC	COSY	NOESY
1	49.1(5), 118.1(14b), 141.5(10),203.6(3)	2.54(2 β), 2.63(2 α)	4.90(14b)
2 α	203.6(3)	3.22(1)	-
2 β	203.6(3)	3.22(1)	4.90(14b)
3	2.54(2 β), 2.63(2 α),3.22(1), 5.90(15a), 6.30(15b)	-	-
4	-	-	-
5	-	4.11(6), 5.90(15a), 6.30(15b)	-
6	74.5(8)	3.29(5), 3.43(7)	5.13(8)
7	-	4.11(6), 5.13(8), 5.80(13b), 6.33(13a)	-
8	-	2.33(9 α), 2.92(9 β),3.43(7)	4.11(6)
9 α	74.5(8), 118.1(14b)	2.92(9 β),5.13(8)	-
9 β	46.8(7), 118.1(14b)	2.33(9 α),5.13(8)	-
10	3.22(1)	-	-
12	5.80(13b), 6.33(13a)	-	-
13a	24.0(12),46.8(7)	3.43(7)	5.80(13b)
13b	24.0(12)	3.43(7)	6.33(13a)
14a	40.9(1)	-	-
14b	40.9(1)	-	2.54(2 β),3.22(1)
15a	49.1(5),203.6(3)	3.29(5), 6.30(15b)	6.30(15b)
15b	49.1(5),203.6(3)	3.29(5), 5.90(15a)	5.90(15a)
1'	6.00(3'a)	-	-
2'	4.40(4'), 6.35(3'b)	-	-
3'a	62.5(4'),165.0(1')	4.40(4'), 6.35(3'b)	4.40(4'), 6.35(3'b)
3'b	62.5(4'),139.3(2')	4.40(4'), 6.00(3'a)	6.00(3'a)
4'	139.3(2')	6.00(3'a),6.35(3'b)	6.00(3'a)




Figure S45: 6 (Dehydrocynaropicrin) 1D-¹H Proton NMR Spectrum




Figure S46: 6 (Dehydrocynaropicrin) ¹³C (APT) 1D-NMR Spectrum




Figure S47: 6 (Dehydrocynaropicrin) COSY 2D-NMR Spectrum




Figure S48: 6 (Dehydrocynaropicrin) HSQC 2D-NMR Spectrum




Figure 49: 6 (Dehydrocynaropirin) HMBC 2D-NMR Spectrum





Figure S50: 6 (Dehydrocynaropicrin) NOESY 2D-NMR Spectrum

7. 1A (11,13, 2', 3'-tetrahydrocynaropicrin)



¹H NMR (500 MHz, CDCl₃); δ 5.42 (t, J = 2.0 Hz, 1H, 15b), 5.33 (t, J = 2.0 Hz, 1H, 15a), 5.16 – 5.11 (m, 1H, 14b), 5.03 (s, 1H, 14a), 4.97 (dtd, J = 10.3, 5.2, 2.7 Hz, 1H, 8), 4.55 (tt, J = 7.1, 2.0 Hz, 1H, 3), 4.13 (td, J = 9.9, 2.7 Hz, 1H, 6), 3.81 – 3.68 (m, 2H, 4'), 2.97 – 2.88 (m, 1H, 1), 2.82 (td, J = 9.4, 2.0 Hz, 1H, 5), 2.70 (dddt, J = 14.8, 9.9, 7.4, 3.8 Hz, 2H, 9 α), 2.57 – 2.46 (m, 1H, 11), 2.33 – 2.27 (m, 1H, 2 β), 2.26 – 2.23 (m, 1H, 7), 2.23 – 2.18 (m, 1H, 9 β), 1.74 (dddd, J = 13.6, 9.4, 7.0, 2.4 Hz, 1H, 2 α), 1.30 (dd, J = 7.0, 2.1 Hz, 3H), 1.21 (d, J = 7.3 Hz, 3H, 3', 13).

¹³C NMR (126 MHz, CDCl₃); δ 177.88 (12), 175.01 (1'), 152.83 (4), 142.18 (10), 117.54 (14), 112.65 (15), 79.00 (6), 76.16 (8), 73.73 (3), 64.47 (4'), 53.19, 50.85 (5), 44.42 (1), 42.17 (2'), 41.48 (11), 40.39 (9), 38.94 (2), 15.66 (13), 13.64 (3').

Table S8: 1A HMBC, COSY, NOESY correlations

No	HMBC	COSY	NOESY
1	38.9(2 β), 50.8(5), 79.0(6), 117.5(14b), 142.2(10)	2.82(5), 2.92(1), 5.14(14b)	4.55(3), 5.14(14b)
2 α	44.4(1), 73.7(3), 142.2(10)	4.55(3)	-
2 β	152.8(4)	-	-
3	-	1.74(2 α), 5.42(15b)	2.82(5), 2.92(1), 5.33(15a)
4	2.29(2 β), 2.82(5), 5.42(15b)	-	-
5	38.9(2 β), 44.4(1), 79.0(6), 112.6(15b), 152.8(4)	2.92(1), 4.13(6), 5.33(15a), 5.42(15b)	4.55(3)
6	76.2(8)	2.26(7), 2.82(5)	2.51(11), 4.97(8), 5.42(15b)
7	15.7(13)	2.21(9 β), 2.72(9 α), 4.13(6), 4.97(8)	1.26(13), 2.72(9 α)
8	142.2(10), 175.0(1')	2.26(7), 2.72(9 α)	2.51(11), 4.13(6)
9 α	53.3(7)	2.21(9 β), 2.26(7), 4.97(8)	2.21(9 β), 2.26(7)
9 β	76.2(8), 117.5(14b), 142.2(10)	2.26(7), 2.72(9 α)	2.72(9 α)
10	1.74(2 α), 2.21(9 β), 2.92(1), 4.97(8)	-	-
11	15.7(13), 53.3(7), 76.2(8), 177.9(12)	-	4.13(6), 4.97(8)
12	2.51(11)	-	-
13	-	-	2.26(7)
14a	40.4(9 β)	-	-
14b	40.4(9 β)	2.92(1)	2.92(1)
15a	50.8(5)	2.82(5)	4.55(3)
15b	50.8(5), 73.7(3), 152.8(4)	2.82(5), 4.55(3)	4.13(6)
1'	1.21(3'), 3.76(4'), 4.97(8)	-	-
2'	-	-	-
3'	64.5(4'), 175.0(1')	-	3.76(4')
4'	175.0(1')	-	1.21(3')




Figure S51: 1A 1D-¹H Proton NMR Spectrum




Figure S52: 1A ¹³C (APT) 1D-NMR Spectrum




Figure S53: 1A HSQC 2D-NMR Spectrum



Figure S55: 1A HMBC 2D-NMR Spectrum





Figure S56: 1A NOESY 2D-NMR Spectrum

8. 1B (Deacylcynaropocrin)



¹H NMR (500 MHz, CDCl₃) δ; 6.27 (dd, *J* = 3.4, 0.9 Hz, 1H, 13b), 6.15 (dd, *J* = 3.2, 0.9 Hz, 1H, 13a), 5.50 (t, *J* = 1.8 Hz, 1H, 15a), 5.35 (t, *J* = 1.8 Hz, 1H, 15b), 5.14 (s, 1H, 14a), 4.98 (s, 1H, 14b), 4.56 (s, 1H, 3), 4.16 (dd, *J* = 10.6, 8.9 Hz, 1H, 6), 3.97 (m, 1H, 8), 2.98 (dt, *J* = 10.9, 8.2 Hz, 1H, 1), 2.80 (m, 2H, 5, 7), 2.71 (dd, *J* = 14.1, 5.1 Hz, 1H, 9a), 2.30 (dd, *J* = 14.1, 3.9 Hz, 1H, 9b), 2.24 (dt, *J* = 13.1, 7.4 Hz, 1H, 2a), 1.74 (m, 1H, 2b).

¹³C NMR (126 MHz, CDCl₃) δ; 152.69 (4), 142.92 (10), 138.19, 123.28 (13), 117.34 (14), 113.44 (15), 78.83, 73.97, 72.19, 51.61 (7), 51.25 (5), 45.52, 41.37 (9), 39.55 (2).

Table S9: 1B HMBC and COSY correlations

No	HMBC	COSY
1	-	1.74(2b), 2.24(2a)
2a	74.1(3), 152.7(4)	1.74(2b), 2.97(1),4.56(3)
2b	-	2.24(2a), 2.97(1),4.56(3)
3	-	1.74(2b), 2.24(2a), 5.35(15b), 5.50(15a)
4	2.24(2a)	-
5	-	5.35(15b)
6	-	2.80(7)
7	-	3.97(8),4.16(6), 6.15(13a), 6.27(13b)
8	-	2.30(9b), 2.71(9a),2.80(7)
9a	45.6(1), 117.3(14b)	2.30(9b),3.97(8), 4.98(14b), 5.14(14a)
9b	72.3(8)	2.71(9a),3.97(8), 4.98(14b)
10	-	-
11	6.27(13b)	-
12	6.15(13a),6.27(13b)	-
13a	51.6(7), 169.6(12)	2.80(7)
13b	51.6(7), 138.2(11), 169.6(12)	2.80(7)
14a	41.4(9b),45.6(1)	2.71(9a)
14b	41.4(9b),45.6(1)	2.30(9b), 2.71(9a)
15a	-	4.56(3)
15b	-	2.80(5),4.56(3)



Figure S57: 1b 1D-¹H Proton NMR Spectrum




Figure S58: 1B ¹³C (APT) 1D-NMR Spectrum




Figure S59: 1B COSY 2D-NMR Spectrum




Figure S60: 1B HSQC 2D-NMR Spectrum

